[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-recurrent-or-metastatic-escc-patients-who-have-failed-prior-pd-1pd-l1-inhibitors-combined-with-platinum-based-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-recurrent-or-metastatic-escc-patients-who-have-failed-prior-pd-1pd-l1-inhibitors-combined-with-platinum-based-chemotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100653656","phase-3-fh-006-versus-investigators-choice-of-chemotherapy-in-patients-with-locally-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma-who-have-failed-prior-pd-1pd-l1-inhibitor-combined-with-platinum-based-chemotherapy-100653656",false,"NCT07790380","FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1\u002FPD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.","A Randomized, Open-label, Multicenter, Phase III Study of FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1\u002FPD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.","Inclusion Criteria:\n\n1. Age 18 to 75 years old (including boundary values)\n2. Volunteer to participate in this clinical study and sign informed consent;\n3. ECOG score 0-1;\n4. Expected survival ≥3 months;\n5. Patients diagnosed with esophageal squamous cell carcinoma by histological or cytological examination;\n6. Previously, only PD-1\u002FPD-L1 Inhibitor Combined With Platinum-Based Chemotherapy were received;\n7. There is at least one measurable lesion that meets the RECIST 1.1 criteria;\n8. Adequate bone marrow and organ function.\n\nExclusion Criteria:\n\n1. Received anti-tumor therapies such as chemotherapy, radiotherapy, biological therapy, targeted therapy, or immunotherapy within 4 weeks before the first dose of the study\n2. Toxicities caused by previous anticancer therapy were not recovered to CTCAE 6.0 Grade≤1;\n3. Individuals with Leptomeningeal metastasis or Active brain metastases;\n4. Individuals with a history of GI perforation or fistula, unstable GI bleeding;\n5. Individuals with a history of severe cardiovascular and cerebrovascular diseases;\n6. The researcher determined that there are other situations that are not suitable for participation.","ALL","18 Years","75 Years",{"count":20,"type":21},480,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.",[27],"Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1\u002FPD-L1 Inhibitors Combined With Platinum-based Chemotherapy","NOT_YET_RECRUITING","2026-08-25",{"date":31,"type":32},"2026-08-27","ACTUAL",{"date":34,"type":21},"2026-10-10",{"date":36,"type":21},"2029-06-30",{"name":38,"class":39},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY"]